The latest update is out from Shionogi & Co ( (JP:4507) ).

Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will share17 scientific presentations from across its ...

In a high-stakes game for both companies, Shionogi is doubling down on its Tetra Therapeutics R&D deal with a buyout option wedded to key data coming out this month. The pair’s original pact was ...

The latest update is out from Shionogi & Co ( (JP:4507) ).

Shionogi & Co. Ltd. (4507.TO) Osaka Half-Year Ended September 30 GROUP 2025 2024 Revenue Y212.97 bln Y213.97 bln Operating Profit Y74.77 bln Y75.87 bln Pretax Profit Y98.38 bln Y93.83 bln Net Profit ...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a pharmaceutical company with a significant focus on infectious diseases, announced today the expanded leadership roles of executive vice president ...

For most drugmakers, it pays to focus on high-priced drugs in new treatment areas. But Japan’s Shionogi is counting on the opposite. Shionogi CEO Isao Teshirogi told Bloomberg that the company, which ...

Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to treat Pompe disease. The agreement grants Shionogi the sole ...

FLORHAM PARK, N.J., April 7, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial ...

Isao Teshirogi, President and CEO at Shionogi & Co Ltd, speaks during an interview with Reuters in Tokyo TOKYO (Reuters) -Japan's Shionogi & Co Ltd said on Wednesday its oral treatment for COVID-19 ...

TOKYO, Nov 22 (Reuters) - Shares in Japanese drugmaker Shionogi & Co Ltd 4507.T rose nearly 3% by mid-morning on Tuesday after the Yomiuri newspaper said the country's regulatory agency had compiled a ...

Shionogi is about to find out what it takes to get a COVID-19 antiviral to market in Japan. Having missed the primary clinical endpoint in a phase 2b, Shionogi has filed for approval on the strength ...